New malaria combo aims to stop relapses for good

NCT ID NCT07430592

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: R. Kiplin Guy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This Phase 2b trial tests whether a new drug, SJ733, combined with tafenoquine can cure P. vivax malaria and prevent it from returning. About 104 adults with uncomplicated malaria will receive different schedules of SJ733 plus tafenoquine, or standard chloroquine plus tafenoquine. The study will check if the combination clears the parasite and keeps it away for 180 days, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SJ733 and tafenoquine
What this could lead to: If successful, this could provide a shorter, more effective treatment to cure P. vivax malaria and prevent it from coming back.
What could go wrong: This is an early Phase 2b trial with only 104 participants. The combination may not work better than existing treatments, and side effects like anemia or low white blood cell counts are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malaria Plasmodium vivax malaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALARIA MALARIA VIVAX RADICAL CURE

Contacts and locations

Locations

Asociación Civil Selva Amazónica (ACSA)

Iquitos, Loreto, Peru

More trials for these conditions

Other studies related to the condition(s) this trial covers.